Urology

Two studies suggest no harm from deferred cytoreduction, potential benefits of immunotherapy

40% of women who received a 3-month course of MV140 had no UTIs during 9-month follow-up

Vasectomy consults more than doubled in the 3 months after Dobbs compared with the year before

PDE5 inhibitors lowered risk of CHF, MI, overall mortality in men with ED and CVD

Combo has potential to be new standard of care in patients with high-risk BCR, expert says

ODAC votes that olaparib-abiraterone combination should be restricted to BRCA-positive subset

The law discriminates against transgender children "based solely on who they are," lawsuit says

Health news and commentary from around the Web gathered by MedPage Today staff

Agency asking ODAC if olaparib-abiraterone should be reserved for BRCA-positive subset

ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

PSA screening rates over 50% for men 70 and up, despite USPSTF recommendations against it

Enfortumab vedotin plus pembrolizumab approved for cisplatin-ineligible patients

Duration of response reaches 18.6 months with belzutifan plus cabozantinib